Characterisation of human dipeptidyl peptidase IV expressed in Pichia pastoris.: A structural and mechanistic comparison between the recombinant human and the purified porcine enzyme

被引:19
作者
Bär, J [1 ]
Weber, A [1 ]
Hoffmann, T [1 ]
Stork, J [1 ]
Wermann, M [1 ]
Wagner, L [1 ]
Aust, S [1 ]
Gerhartz, B [1 ]
Demuth, HU [1 ]
机构
[1] Probiodrug AG, Dept Enzymol, D-06120 Halle Saale, Germany
关键词
adenosine deaminase; dipeptidyl peptidase IV; DNA sequence;
D O I
10.1515/BC.2003.172
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Dipeptidyl peptidase IV/CD26 (DP IV) is a multifunctional serine protease cleaving off dipeptides from the Nterminus of peptides. The enzyme is expressed on the surface of epithelial and endothelial cells as a type II transmembrane protein. However, a soluble form of DPIV is also present in body fluids. Large scale expression of soluble human recombinant His(6)-37 766 DP IV, using the methylotrophic yeast Pichia pastoris, yielded 1.7 mg DP IV protein per litre of fermentation supernatant. The characterisation of recombinant DP IV confirmed proper folding and glycosylation similar to DP IV purified from porcine kidney. Kinetic comparison of both proteins using short synthetic substrates and inhibitors revealed similar characteristics. However, interaction analysis of both proteins with the gastrointestinal hormone GLP-17 36 resulted in significantly different binding constants for the human and the porcine enzyme (K-d=153.0 +/- 17.0 M and K-d=33.4 +/- 2.2 muM, respectively). In contrast, the enzyme adenosine deaminase binds stronger to human than to porcine DP IV (K-d=2.15 +/- 0.18 nM and K-d=7.38 +/- 0.54 nM, respectively). Even though the sequence of porcine DP IV, amplified by RTPCR, revealed 88% identity between both enzymes, the speciesspecific variations between amino acids 328 to 341 are likely to be responsible for the differences in ADA-binding.
引用
收藏
页码:1553 / 1563
页数:11
相关论文
共 47 条
[1]   Binding to human dipeptidyl peptidase IV by adenosine deaminase and antibodies that inhibit ligand binding involves overlapping, discontinuous sites on a predicted β propeller domain [J].
Abbott, CA ;
McCaughan, GW ;
Levy, MT ;
Church, WB ;
Gorrell, MD .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1999, 266 (03) :798-810
[2]  
Augustyns K, 1999, CURR MED CHEM, V6, P311
[3]   IMPROVED SILVER STAINING OF PLANT-PROTEINS, RNA AND DNA IN POLYACRYLAMIDE GELS [J].
BLUM, H ;
BEIER, H ;
GROSS, HJ .
ELECTROPHORESIS, 1987, 8 (02) :93-99
[4]  
BUHLING F, 1994, NAT IMMUN, V13, P270
[5]   RECENT ADVANCES IN THE EXPRESSION OF FOREIGN GENES IN PICHIA-PASTORIS [J].
CREGG, JM ;
VEDVICK, TS ;
RASCHKE, WC .
BIO-TECHNOLOGY, 1993, 11 (08) :905-910
[6]   CD26, let it cut or cut it down [J].
De Meester, I ;
Korom, S ;
Van Damme, J ;
Scharpé, S .
IMMUNOLOGY TODAY, 1999, 20 (08) :367-375
[7]   Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig [J].
Deacon, CF ;
Hughes, TE ;
Holst, JJ .
DIABETES, 1998, 47 (05) :764-769
[8]   DEGRADATION OF GLUCAGON-LIKE PEPTIDE-1 BY HUMAN PLASMA IN-VITRO YIELDS AN N-TERMINALLY TRUNCATED PEPTIDE THAT IS A MAJOR ENDOGENOUS METABOLITE IN-VIVO [J].
DEACON, CF ;
JOHNSEN, AH ;
HOLST, JJ .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1995, 80 (03) :952-957
[9]   BINDING OF ADENOSINE-DEAMINASE TO THE LYMPHOCYTE SURFACE VIA CD26 [J].
DEMEESTER, I ;
VANHAM, G ;
KESTENS, L ;
VANHOOF, G ;
BOSMANS, E ;
GIGASE, P ;
SCHARPE, S .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1994, 24 (03) :566-570
[10]   Use of immobilized adenosine deaminase (EC 3.5.4.4) for the rapid purification of native human CD26 dipeptidyl peptidase IV (EC 3.4.14.5) [J].
DeMeester, I ;
Vanhoof, G ;
Lambeir, AM ;
Scharpe, S .
JOURNAL OF IMMUNOLOGICAL METHODS, 1996, 189 (01) :99-105